TP53BP1 and small cell lung carcinoma: The current study indicated that CUDC-907 treatment led to decreased HR factor Rad51 and NHEJ factor Ku80 and 53BP1, indicating that targeting DSB repair pathways with dual HDAC-PI3K inhibitors is a promising strategy to improve PARPi efficacy in SCLC.